Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use IMAAVY safely and effectively. See full prescribing information for IMAAVY. IMAAVY® (nipocalimab-aahu) injection, for intravenous use Initial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. IMAAVY is indicated for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids.
- generic_name
- nipocalimab-aahu
- product_names
- nipocalimab-aahu
- ndc
- 57894-800, 57894-801, 57894-801-01, 57894-800-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en